Cargando…
Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease
We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to dis...
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864826/ https://www.ncbi.nlm.nih.gov/pubmed/35193708 http://dx.doi.org/10.1186/s13148-022-01246-2 |
| _version_ | 1784655531326046208 |
|---|---|
| author | Vrba, Lukas Futscher, Bernard W. Oshiro, Marc Watts, George S. Menashi, Emmanuel Hu, Charles Hammad, Hytham Pennington, Daniel R. Golconda, Umamaheshwari Gavini, Hemanth Roe, Denise J. Shroff, Rachna T. Nelson, Mark A. |
| author_facet | Vrba, Lukas Futscher, Bernard W. Oshiro, Marc Watts, George S. Menashi, Emmanuel Hu, Charles Hammad, Hytham Pennington, Daniel R. Golconda, Umamaheshwari Gavini, Hemanth Roe, Denise J. Shroff, Rachna T. Nelson, Mark A. |
| author_sort | Vrba, Lukas |
| collection | PubMed |
| description | We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-022-01246-2. |
| format | Online Article Text |
| id | pubmed-8864826 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88648262022-02-23 Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease Vrba, Lukas Futscher, Bernard W. Oshiro, Marc Watts, George S. Menashi, Emmanuel Hu, Charles Hammad, Hytham Pennington, Daniel R. Golconda, Umamaheshwari Gavini, Hemanth Roe, Denise J. Shroff, Rachna T. Nelson, Mark A. Clin Epigenetics Short Report We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-022-01246-2. BioMed Central 2022-02-22 /pmc/articles/PMC8864826/ /pubmed/35193708 http://dx.doi.org/10.1186/s13148-022-01246-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Short Report Vrba, Lukas Futscher, Bernard W. Oshiro, Marc Watts, George S. Menashi, Emmanuel Hu, Charles Hammad, Hytham Pennington, Daniel R. Golconda, Umamaheshwari Gavini, Hemanth Roe, Denise J. Shroff, Rachna T. Nelson, Mark A. Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease |
| title | Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease |
| title_full | Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease |
| title_fullStr | Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease |
| title_full_unstemmed | Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease |
| title_short | Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease |
| title_sort | liquid biopsy, using a novel dna methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease |
| topic | Short Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864826/ https://www.ncbi.nlm.nih.gov/pubmed/35193708 http://dx.doi.org/10.1186/s13148-022-01246-2 |
| work_keys_str_mv | AT vrbalukas liquidbiopsyusinganoveldnamethylationsignaturedistinguishespancreaticadenocarcinomafrombenignpancreaticdisease AT futscherbernardw liquidbiopsyusinganoveldnamethylationsignaturedistinguishespancreaticadenocarcinomafrombenignpancreaticdisease AT oshiromarc liquidbiopsyusinganoveldnamethylationsignaturedistinguishespancreaticadenocarcinomafrombenignpancreaticdisease AT wattsgeorges liquidbiopsyusinganoveldnamethylationsignaturedistinguishespancreaticadenocarcinomafrombenignpancreaticdisease AT menashiemmanuel liquidbiopsyusinganoveldnamethylationsignaturedistinguishespancreaticadenocarcinomafrombenignpancreaticdisease AT hucharles liquidbiopsyusinganoveldnamethylationsignaturedistinguishespancreaticadenocarcinomafrombenignpancreaticdisease AT hammadhytham liquidbiopsyusinganoveldnamethylationsignaturedistinguishespancreaticadenocarcinomafrombenignpancreaticdisease AT penningtondanielr liquidbiopsyusinganoveldnamethylationsignaturedistinguishespancreaticadenocarcinomafrombenignpancreaticdisease AT golcondaumamaheshwari liquidbiopsyusinganoveldnamethylationsignaturedistinguishespancreaticadenocarcinomafrombenignpancreaticdisease AT gavinihemanth liquidbiopsyusinganoveldnamethylationsignaturedistinguishespancreaticadenocarcinomafrombenignpancreaticdisease AT roedenisej liquidbiopsyusinganoveldnamethylationsignaturedistinguishespancreaticadenocarcinomafrombenignpancreaticdisease AT shroffrachnat liquidbiopsyusinganoveldnamethylationsignaturedistinguishespancreaticadenocarcinomafrombenignpancreaticdisease AT nelsonmarka liquidbiopsyusinganoveldnamethylationsignaturedistinguishespancreaticadenocarcinomafrombenignpancreaticdisease |